Related to BMS Awards Grants Focused on Combatting HBV and HCV in China and India

• Sinovac Expands Vaccine Capabilities with New JV
  
• Bayer Schering Pharma Receives Chinese Approval for MS Drug and Signs Anticancer Deal with Micromet
  
• BMS Pays $10M to Tap into Tranzyme’s Macrocyclic Compound Discovery Expertise
  
• EU Gives Dynavax’ German Manufacturing Plant the Nod for Commercial Production of HBV Vaccine
  
• Cambridge University and Chi-Med to Study Angiogenesis Effects of Chinese Medicinal Plants
  
• Meda In-Licenses Commercial Rights to EpiCept’s AML Therapy for $3M
  
• KaloBios Obtains $35M Up Front from Sanofi Pasteur for Clinical Antibody Candidate against Pseudomonas Aeruginosa
  
• GVK Biosciences Joins ResearchPoint Global’s Worldwide CRO Network
  
• GlobeImmune Raises $17.5M in Series E Financing
  
• Optimer Reports Positive Phase III Data for Antibiotic against C. Difficile
  
• Novartis Negotiates Rights to Debiopharm’s Mid-Stage HCV Candidate
  
• LFB Licenses Thallion’s Early-Stage Candidate for Treating STEC Infections
  
• PPD Continues Asia Expansion with Plans for New Facilities in the Philippines and India
  
• GSK and Regulus to Collaborate on miRNA-Based HCV Drugs
  
• BMS’ Transplant-Rejection Drug Passes FDA’s Advisory Panel
  
• BMS Gives Up $40M in Exchange for Allergan’s Neuropathic Pain Drug
  
• Beijing Pioneer to Provide Olink’s Duolink Product Line in China
  
• Japan Sanctions Erbitux as First-Line Treatment for EGFR-Expressing mCRC
  
• ICON and Tigermed Team Up to Facilitate Access to Chinese Patient Populations
  
• Inovio Obtains $2.8M Grant to Advance Preclinical DNA Vaccines for HCV